Healthcare Sector — Q3 FY25 Earnings Overview

3 companies reported. 3 bullish, 0 neutral, 0 bearish.

Average revenue growth: 10.8%

Sector sentiment: bullish

Aggregate revenue: ₹26,037 Cr

Average margin: 23.8%

Company Results

Company	Revenue	YoY	Margin	Sentiment
Sunpharma	₹13,437 Cr	+10.5%	29.3%	bullish high
Cipla	₹7,073 Cr	+8%	28.0%	bullish high
Apollohosp	₹5,527 Cr	+14%	14.0%	bullish high

Key sector risks this quarter

Sunpharma · high

Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.

Sunpharma · high

If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.

Cipla · high

US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.

Cipla · high

Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.

Apollohosp · medium

Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.